Studies have shown that the PTEN gene undergoes significant mutations and deletions in a variety of tumors, including melanoma, breast, prostate and endometrial cancer, resulting in a loss of protein expression or dysfunction, thereby contributing to tumor development (3,4). This evidence concerns the gene PTEN and neoplasm.